Myelofibrosis: Difference between revisions

Jump to navigation Jump to search
Line 87: Line 87:
== References ==
== References ==
{{reflist|2}}
{{reflist|2}}
==See also==
* [[Myelophthisic anemia]]


<br>
<br>

Revision as of 14:24, 19 January 2009

Template:DiseaseDisorder infobox Template:Search infobox Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Myelofibrosis with myeloid metaplasia, also known as agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis, and primary myelofibrosis,[1] was first described in 1879 and is currently classified as a myeloproliferative disease caused by the growth and proliferation of an abnormal bone marrow stem cell, resulting in the replacement of the bone marrow with fibrous connective tissue. An eponym for the disease is Heuck-Assmann disease, or Assmann's Disease.

Epidemiology

The disorder usually develops slowly, in people over 50 years old.

Pathophysiology

The bone marrow is replaced by collagen fibrosis, impairing the patient's ability to generate new blood cells resulting in a progressive pancytopenia. It is usually reactive following other myeloproliferative disorders, such as polycythemia rubra vera or essential thrombocytosis. Extramedullary hematopoeisis occurs as the haemopoetic cells migrate away from the bone marrow, to the liver and spleen. Patients often have hepatosplenomegaly and poikilocytosis.

In primary myelofibrosis, a progressive scarring (fibrosis) of the bone marrow occurs. As a result, blood forms in sites other than the bone marrow, such as the liver and spleen. This causes an enlargement of these organs. The cause and risk factors are unknown. It commonly occurs in the spent phase of Polycythemia rubra vera, possibly in response to the medication hydroxyurea poisoning the marrow.

Genetic associations with JAK2[2] and MPL[3] have been described.

Signs and symptoms

  • Abdominal fullness related to an enlarged spleen (splenomegaly).
  • Bone pain
  • Bruising and easy bleeding due to inadequate numbers of platelets
  • Fatigue
  • Increased susceptibility to infection, such as pneumonia or diarrhea
  • Pallor and shortness of breath while doing physical work due to anemia

Diagnosis

Diagnosis is based upon:

The patient with the myelofibrosis should be tested for Tuberculosis even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.

Diagnostic Findings

MRI

(Images courtesy of RadsWiki)

Treatment

The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.[4]

Other treatment options are largely supportive, and do not alter the course.[5] These options may include regular folic acid, allopurinol or blood transfusions. Dexamethasone, alpha-interferon and hydroxycarbamide may play a role.

Lenalidomide and Thalidomide may be used in its treatment, though they can cause gout and leave the patient susceptible to diseases such as pneumonia.

Frequent blood transfusions may also be required.

Prognosis

Myelofibrosis leads to progressive bone marrow failure. The mean survival is five years and causes of death include infection, bleeding, organ failure, portal hypertension, and leukemic transformation.

References

  1. Older terms include "myelofibrosis with myeloid metaplasia" and "agnogenic myeloid metaplasia". The World Health Organization utilizes the name "chronic idiopathic myelofibrosis", while the International Working Group on Myelofibrosis Research and Treatment calls the disease "primary myelofibrosis".
  2. Baxter EJ, Scott LM, Campbell PJ; et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet. 365 (9464): 1054–61. doi:10.1016/S0140-6736(05)71142-9. PMID 15781101.
  3. Pikman Y, Lee BH, Mercher T; et al. (2006). "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia". PLoS Med. 3 (7): e270. doi:10.1371/journal.pmed.0030270. PMC 1502153. PMID 16834459. Unknown parameter |month= ignored (help)
  4. Cervantes F (2005). "Modern management of myelofibrosis". Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter |month= ignored (help)
  5. Kröger N, Mesa RA (2008). "Choosing between stem cell therapy and drugs in myelofibrosis". Leukemia. 22 (3): 474–86. doi:10.1038/sj.leu.2405080. PMID 18185525. Unknown parameter |month= ignored (help)

See also


Template:Hematology

Template:SIB

bn:মজ্জাকাঠিন্য de:Osteomyelofibrose it:Mielofibrosi

Template:WH Template:WS